key: cord-0975711-ng70761t
authors: Kavanal, Anwin Joseph; Jena, Santosh Ranjan; Kumar, Rajender; Das, Chandan Krushna; Kumar, Sunil; Mittal, Bhagwant Rai
title: Effect of COVID-19 on (18)F-FDG PET/CT: Is There a Need to Consider COVID-19 Status Before Planning (18)F-FDG PET/CT for Oncologic Evaluation?
date: 2021-09-03
journal: J Nucl Med Technol
DOI: 10.2967/jnmt.121.262145
sha: 447bbb8d381a5a1df99ca150d7b74b1be78da238
doc_id: 975711
cord_uid: ng70761t

Incidental detection of coronavirus disease 2019 (COVID-19)–related lung changes on (18)F-FDG PET/CT images of oncology patients has been increasingly reported. Most of the case reports or series have stressed the retrospective diagnosis of COVID-19 with the help of (18)F-FDG PET/CT lung findings. In this case report, we introduce a different aspect of COVID-19–related lung changes on (18)F-FDG PET/CT, interfering with the evaluation of metastatic lung lesions in a patient with renal cell carcinoma.

Vari ous lung involvement patterns have been reported on 18 F-FDG PET/CT scans of coronavirus disease 2019 (COVID-19) patients undergoing workup for various malignancies. The patterns range from 18 F-FDG-avid diffuse ground-glass opacities to 18 F-FDG-avid patchy consolidatory changes, with or without 18 F-FDG-avid mediastinal lymph nodes, depending on the imaging time from the onset of infection and other unknown factors (1) (2) (3) (4) . COVID-19 infection was a retrospective diagnosis in most reported cases, after the typical findings were seen on the 18 F-FDG PET/CT images (3) (4) (5) (6) (7) . Here, we present a different aspect of COVID-19 on 18 F-FDG PET/CT, in which there was interference with response assessment in a patient receiving chemotherapy for pulmonary metastasis from renal cell carcinoma.

A 45 y-old man with a known case of metastatic renal cell carcinoma underwent cytoreduction nephrectomy followed by first-line chemotherapy with pembrolizumab and axitinib because of multiple cannonball metastases in the lungs. 18 F-FDG PET/CT at the end of treatment showed disease progression in the form of an increase in the number and size of lung nodules. The patient was then started on second-line chemotherapy with oral lenvatinib (18 mg daily) and everolimus (5 mg daily). His interim 18 F-FDG PET/CT scan (Fig. 1) showed a favorable response (.30% reduction in size and 18 F-FDG avidity compared with baseline PET/CT) to second-line therapy, and he was continued on the same treatment. He was diagnosed with COVID-19 in May 2020 on evaluation for malaise and chills. He was managed conservatively with antibiotics, antipyretics, and multivitamins in a local hospital. He had no symptoms or signs suggestive of pneumonia and never required oxygen support during the 11-d course in the hospital. He was discharged from the hospital after a negative nucleic acid test 1 wk before he was scheduled for an 18 F-FDG PET/CT scan at 6 mo of chemotherapy to determine the response. The 18 F-FDG PET/CT scan (Fig. 2) showed 18 F-FDG-avid diffuse ground-glass opacities/patchy consolidatory changes bilaterally in the lung fields from apex to base, obscuring the metastatic lesions. The COVID-19-related lung changes obscured both the anatomic and the metabolic features of the metastatic lesions, leading to difficulty in assessing the response to treatment.

F-FDG uptake in ground-glass opacities in the background may add spill-in counts to metastatic lesions, causing a falsely high uptake in metastatic lesions (8) . For this reason, an accurate assessment of the metabolic response was not possible in this patient. The patient was advised to repeat the nucleic acid test because of 18 F-FDG avidity in the ground-glass opacities/ consolidatory changes and was found to be positive. The patient was then advised to remain home in isolation again.

During the COVID-19 pandemic phase, we have to consider sources of possible interference such as described in this report before scheduling patients for 18 F-FDG PET/CT scans for various oncologic purposes.

No potential conflict of interest relevant to this article was reported.

18 F]FDG-PET/CT in different COVID-19 phases

18 FDG-PET/CT findings in COVID-19: a single centre retrospective radiological review

18 F-FDG PET/CT and serial chest CT findings in a COVID-19 patient with dynamic clinical characteristics in different period

18 F-FDG PET/CT in asymptomatic patients with COVID-19: the submerged iceberg surfaces

The potential added value of FDG PET/CT for COVID-19 pneumonia

A case of coronavirus infection incidentally found on FDG PET/CT scan

FDG PET/CT findings in an asymptomatic case of confirmed COVID-19

Validation of the physiological background correction method for the suppression of the spill-in effect near highly radioactive regions in positron emission tomography

axial PET/CT images (B), and corresponding CT images (C) showing 18 F-FDG-avid diffuse ground-glass opacities/patchy consolidatory changes bilaterally in lung fields from apex to base, obscuring details of metastatic lesions